KX2-391

Athenex, Inc. · Phase 2 active Small molecule

KX2-391, a novel small molecule developed by Athenex, Inc., is in advanced clinical trials for actinic keratosis and has shown promise in treating bone-metastatic, castration-resistant prostate cancer. The drug's unique mechanism of action and favorable safety profile make it a potential best-in-class therapy.

At a glance

Generic name	KX2-391
Also known as	KXO1, KX01
Sponsor	Athenex, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KX2-391 CI brief — competitive landscape report
KX2-391 updates RSS · CI watch RSS
Athenex, Inc. portfolio CI